KLP Kapitalforvaltning AS Invests $509,000 in LivaNova PLC (NASDAQ:LIVN)

KLP Kapitalforvaltning AS bought a new stake in shares of LivaNova PLC ( NASDAQ:LIVN – Free Report ) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,000 shares of the company’s stock, valued at approximately $509,000. Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company.

American Century Companies Inc. grew its stake in shares of LivaNova by 32.9% during the fourth quarter.



American Century Companies Inc. now owns 150,760 shares of the company’s stock worth $6,982,000 after acquiring an additional 37,306 shares during the last quarter. Xponance Inc.

boosted its stake in LivaNova by 6.1% in the 4th quarter. Xponance Inc.

now owns 7,762 shares of the company’s stock worth $359,000 after purchasing an additional 445 shares in the last quarter. Cibc World Markets Corp purchased a new stake in LivaNova during the 4th quarter worth approximately $236,000. Vestcor Inc acquired a new position in LivaNova during the 4th quarter valued at approximately $204,000.

Finally, Swiss National Bank raised its holdings in shares of LivaNova by 0.7% in the fourth quarter. Swiss National Bank now owns 106,819 shares of the company’s stock worth $4,947,000 after buying an additional 700 shares during the last quarter.

97.64% of the stock is currently owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth A number of equities research analysts have recently weighed in on the stock.

Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Mizuho dropped their price target on LivaNova from $70.00 to $60.

00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group reduced their price objective on LivaNova from $64.00 to $55.

00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Barclays decreased their target price on LivaNova from $58.00 to $56.

00 and set an “equal weight” rating for the company in a report on Friday, March 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of LivaNova in a report on Monday, March 17th.

Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $61.17.

LivaNova Stock Down 5.1 % LivaNova stock opened at $37.48 on Friday.

LivaNova PLC has a 52 week low of $36.85 and a 52 week high of $64.48.

The firm has a market cap of $2.04 billion, a price-to-earnings ratio of 89.24 and a beta of 0.

90. The business’s 50-day moving average price is $43.71 and its 200 day moving average price is $48.

21. The company has a quick ratio of 2.87, a current ratio of 3.

37 and a debt-to-equity ratio of 0.46. About LivaNova ( Free Report ) LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide.

The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. See Also Five stocks we like better than LivaNova Are Penny Stocks a Good Fit for Your Portfolio? Shares of RH Down Nearly 40%: Where Investors Can Turn To Now How to Calculate Inflation Rate Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian What is a Dividend King? Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.

com's FREE daily email newsletter ..